Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal 1

4410 - A Phase 3 Study of Nivolumab (Nivo) in Previously Treated Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Updated Results and Subset Analysis by PD-L1 Expression (ATTRACTION-02)

Date

08 Sep 2017

Session

Gastrointestinal tumours, non-colorectal 1

Topics

Immunotherapy;  Oesophageal Cancer;  Gastric Cancer;  Prostate Cancer

Presenters

Narikazu Boku

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

N. Boku1, Y. Kang2, T. Satoh3, Y. Chao4, K. Kato5, H.C. Chung6, J. Chen7, K. Muro8, W.K. Kang9, T. Yoshikawa10, S.C. Oh11, T. Tamura12, K. Lee13, L. Chen14

Author affiliations

  • 1 Division Of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 3 Department Of Frontier Science For Cancer And Chemotherapy, Osaka University Graduate School of Medicine, 565-0871 - Suita/JP
  • 4 Oncology, Taipei Veterans General Hospital, Taipei/TW
  • 5 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 6 Department Of Internal Medicine, Yonsei Cancer Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, 120-752 - Seoul/KR
  • 7 Department Of Internal Medicine, Chang Gung Memorial Hospital-Linkou, 333 - Taoyuan/TW
  • 8 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 9 Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 10 Department Of Gastrointestinal Surgery, Kanagawa Cancer Center, 2418515 - Yokohama/JP
  • 11 Division Of Hematology/oncology, Internal Medicine Department, College of Medicine, Korea University, Seoul, Korea, Seoul/KR
  • 12 Medical Oncology, Kindai University Faculty of Medicine, Osaka/JP
  • 13 Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam/KR
  • 14 National Institute Of Cancer Research, National Health Research Institutes, and National Cheng Kung University Hospital,, 704 - Tainan/TW
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4410

Background

Nivo monotherapy demonstrated its efficacy with manageable safety for G/GEJ cancer refractory or intolerant to standard chemotherapy at the primary analysis (ATTRACTION-02[ONO-4538-12]: ASCO-GI 2017, Kang YK et al. J Clin Oncol. 2017; 35 [suppl 4S abstract 2]). Here, we report updated results, and the relationship between efficacy of Nivo and PD-L1 expression levels.

Methods

493 patients(pts) aged ≥ 20 years with ECOG PS 0-1 and unresectable advanced or recurrent G/GEJ cancer after failure of two or more previous chemotherapy regimens were randomized in a 2:1 ratio to receive 3 mg/kg Nivo (N = 330) or placebo (N = 163) every 2 weeks until unacceptable toxicity or disease progression. The primary endpoint was overall survival (OS). The PD-L1 expression was assessed by immunohistochemistry (28-8 pharmDx assay). And updated results of the efficacy and safety were based on ≥ 1-year follow-up after last patient enrollment.

Results

As of the data cut-off on February 25th 2017, one year after last patient enrollment, the median OS (mOS) was 5.32 months with Nivo versus 4.14 months with placebo (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.50-0.75; p 

Conclusions

With minimum 1-year of follow-up, long-term survival benefit of nivolumab was confirmed for patients with advanced G/GEJ cancer. Although tumor samples were available only in 40% of all enrolled patients, Nivo demonstrated benefit irrespective of PD-L1 expression in the exploratory analysis.

Clinical trial identification

NCT02267343

Legal entity responsible for the study

Ono Pharmaceutical Co., Ltd

Funding

Ono Pharmaceutical Co., Ltd, Bristol-Myers Squibb

Disclosure

N. Boku: Ono, Taiho, Chugai, Eli-Lilly. Y-K. Kang: Ono, Bristol-Myers Squibb, Lilly/ImClone, Taiho Pharmaceutical, Roche/Genentech, Novartis, Bayer. T. Satoh: Ono. K. Kato: Ono, Shionogi, MSD. H.C. Chung: Lilly, GSK, MSD, Merck Serono, BMS, Ono, Taiho, Celltrion, Quintiles, BMS. K. Muro: Shionogi, MSD K.K., Daiichi Sankyo, Kyowa Hakko Kirin, Gilead Sciences, Chugai, Takeda, Eli Lilly Japan K.K., Merck Serono, Taiho, Yakult Honsha. T. Yoshikawa: Taiho, Chugai, Yakult, Ono, MSD. K-W. Lee: Ono. L-T. Chen: Ono, Eli-Lilly, MSD, PharmaEngine, Merrimack, TTY, Syncore, Five Prime, Novartis, GSK, Merck Serono, Polaris, Anti-Alpha Enolase (ENO-1) monoclonal antibody/HuniLife. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.